Navigation Links
OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Date:9/3/2009

BOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences:

    -   Rodman & Renshaw 11th Annual Healthcare Conference on Thursday,
        September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon
        at the New York Palace Hotel in New York City.

    -   Thomas Weisel Partners Healthcare Conference on Friday, September 11,
        2009 at 10:20 a.m. Eastern Time in the Stuart Room at the Four
        Seasons Hotel in Boston.

    -   BioCentury NewsMakers in the Biotech Industry Conference on
        Wednesday, September 16, 2009 at 2:30 p.m. Eastern Time in room
        304/305 at the Millennium Broadway Hotel & Conference Center in New
        York City.

Access to a live webcast of each of the presentations will be available on the Events Presentation section of the Investor Relations page on the company Web site at www.oncogenex.com. A replay of each webcast will be available for 30 days following the event.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical develo
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound marketing ... Gig LLC to provide website design, development, and creative ... alliance with Designing Gig represents a pivotal moment for ... end-to-end, digital solution for our clients, which now includes ... president of The Market Element. “For small and mid-sized ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... Phase 2 clinical trial using intravenous,administration of REOLYSIN(R) ... advanced head and neck cancers. The Principal,Investigator is ... Research Center,(CTRC) at The University of Texas Health ...
... Inc. (Amex:,SGN) announced that it has filed its Form ... of trading of its common stock,on the American Stock ... trade on AMEX will be Friday, September 12, 2008.,Signalife ... for,quotation on both the Over-The-Counter Bulletin Board and the ...
... 8 On Wednesday, October,22, 2008, Wyeth (NYSE: ... quarter. The Company will hold a one-hour conference call ... 22, 2008. Interested,investors and others may listen to the ... webcast, which may be accessed by visiting our website,at ...
Cached Biology Technology:Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Signalife Announces Anticipated Date of Transition to OTCBB 2
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... 18th century natural philosopher Jean-Baptiste Lamarck proposed that the ... cumulative effort, across generations, to reach leaves just out ... abandoned with the advent of modern genetic theories to ... medical illnesses across generations. However, there has long ...
... February 13, 2013, Cleveland: Cleveland Clinic researchers have found ... genetic screening for Lynch syndrome, the most common hereditary, ... online version of the Journal of Clinical Oncology ... cause of colon cancer in adults. The study found ...
... can affect the knowledge and behaviour of their parents, ... London surveyed the families of 160 schoolchildren in the ... about the island,s valuable wetland resources. They found ... the wetland activities were more knowledgeable about wetlands and, ...
Cached Biology News:Life experiences put their stamp on the next generation: New insights from epigenetics 2Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer 2Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer 3Environment schemes for kids influence parents' behavior 2
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
... The features we add to WinList ... the product every day. Features like automatic ... are the result of good suggestions, thoughtful ... of the features you depend on are ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: